Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Dow
Cipla
Citi
Mallinckrodt
Deloitte
QuintilesIMS
Express Scripts
US Army

Generated: August 17, 2017

DrugPatentWatch Database Preview

FIRMAGON Drug Profile

« Back to Dashboard

Which patents cover Firmagon, and what generic Firmagon alternatives are available?

Firmagon is a drug marketed by Ferring and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and nine patent family members in thirty-six countries.

The generic ingredient in FIRMAGON is degarelix acetate. One supplier is listed for this compound. Additional details are available on the degarelix acetate profile page.

Summary for Tradename: FIRMAGON

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list14
Clinical Trials: see list38
Patent Applications: see list8
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:FIRMAGON at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring
FIRMAGON
degarelix acetate
POWDER;SUBCUTANEOUS022201-001Dec 24, 2008RXYesNo► Subscribe► Subscribe ► Subscribe
Ferring
FIRMAGON
degarelix acetate
POWDER;SUBCUTANEOUS022201-002Dec 24, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Ferring
FIRMAGON
degarelix acetate
POWDER;SUBCUTANEOUS022201-001Dec 24, 2008RXYesNo► Subscribe► Subscribe ► Subscribe
Ferring
FIRMAGON
degarelix acetate
POWDER;SUBCUTANEOUS022201-001Dec 24, 2008RXYesNo► Subscribe► SubscribeYY ► Subscribe
Ferring
FIRMAGON
degarelix acetate
POWDER;SUBCUTANEOUS022201-002Dec 24, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: FIRMAGON

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,214,798 GnRH antagonists being modified in positions 5 and 6► Subscribe
8,841,081Method of treating metastatic stage prostate cancer► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FIRMAGON

Country Document Number Estimated Expiration
South Korea20100126362► Subscribe
Russian Federation2504393► Subscribe
China1230442► Subscribe
Russian Federation2504394► Subscribe
Portugal2650012► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FIRMAGON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1003774/01Switzerland► SubscribePRODUCT NAME: DEGARELIX; REGISTRATION NUMBER/DATE: SWISSMEDIC 59455 12.02.2010
C0028France► SubscribePRODUCT NAME: DEGARELIX, SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/504/001 DU 20090217; REGISTRATION NO/DATE AT EEC: EU/1/08/504/001 DU 20090217
2009 00022Denmark► Subscribe
2009005Lithuania► SubscribePRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
C020/2009Ireland► SubscribeSPC020/2009: 20091119, EXPIRES: 20230412
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Mallinckrodt
Healthtrust
Harvard Business School
Merck
US Army
QuintilesIMS
Cipla
Argus Health
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot